Compare ORLY & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORLY | REGN |
|---|---|---|
| Founded | 1957 | 1988 |
| Country | United States | United States |
| Employees | N/A | 15410 |
| Industry | Auto & Home Supply Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.0B | 68.8B |
| IPO Year | 1996 | 1995 |
| Metric | ORLY | REGN |
|---|---|---|
| Price | $87.40 | $656.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 25 |
| Target Price | $111.59 | ★ $830.16 |
| AVG Volume (30 Days) | ★ 8.0M | 720.4K |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 0.55% |
| EPS Growth | N/A | ★ 8.19 |
| EPS | 0.72 | ★ 6.75 |
| Revenue | ★ $17,781,992,000.00 | $5,872,227,000.00 |
| Revenue This Year | $8.67 | $12.45 |
| Revenue Next Year | $6.22 | $10.13 |
| P/E Ratio | $119.60 | ★ $96.58 |
| Revenue Growth | 6.42 | ★ 20.82 |
| 52 Week Low | $82.59 | $541.00 |
| 52 Week High | $108.72 | $821.11 |
| Indicator | ORLY | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 48.75 | 52.60 |
| Support Level | $83.85 | $648.66 |
| Resistance Level | $94.13 | $670.96 |
| Average True Range (ATR) | 2.28 | 15.37 |
| MACD | 0.17 | -0.65 |
| Stochastic Oscillator | 51.56 | 40.76 |
O'Reilly is an aftermarket automotive parts retailer in the United States and Mexico with more than $16 billion in annual sales. The company operates over 6,000 domestic stores and serves both the do-it-yourself (about 50% of sales) and professional (47% of sales) end markets. O'Reilly differentiates itself by providing quality service to its customers throughout the entirety of the vehicle diagnosis and purchasing process. Furthermore, the firm boasts an impressive hub-and-spoke distribution network designed to provide its localized store base with ample aftermarket part availability across a variety of vehicle makes and models.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.